Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal for Immunotherapy of Cancer|December 15, 2022
Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19<sup>+</sup> malignancyChristopher A Pennell, Heather Campbell, Meghan D Storlie, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2002
The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivoLisa A E Harmala, Elizabeth G Ingulli, Julie M Curtsinger, et al.Nature Communications|February 6, 2019
Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapyPamela C Rosato, Sathi Wijeyesinghe, J Michael Stolley, et al.Journal for Immunotherapy of Cancer|January 20, 2015
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapyChristopher L Moertel, Junzhe Xia, Rebecca LaRue, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|May 22, 2013
Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responsesWynette M Dietz, Nicole E B Skinner, Sara E Hamilton, et al.JCI Insight|August 2, 2022
Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responsesSara Bolivar-Wagers, Michael L Loschi, Sujeong Jin, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|May 9, 2018
Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic MiceChristopher A Pennell, Jessie L Barnum, Cameron S McDonald-Hyman, et al.JCI Insight|July 14, 2026
CAR19 Tregs treat murine chronic Graft-Versus-Host Disease through immune suppression in absence of measurable B-cell cytolysisSujeong Jin, Michael C Zaiken, Cameron McDonald-Hyman, et al.Pageof 2